Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with heparin (moderate certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with heparin (high certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ clinically relevant, non‐major Treatment duration 28 ‐ 42… compared with heparin (high certainty).
1 finding from 1 review
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with heparin (high certainty).
1 finding from 1 review
Intervention not reported
Arterial thrombotic events (6 to 48 hours after CC) · children with congenital heart disease undergoing CC
The intervention showed no clear difference in arterial thrombotic events (6 to 48 hours after CC) (moderate certainty).
1 finding from 1 review
Intervention not reported
Major bleeding events (timing not specified) · children with congenital heart disease undergoing CC
The intervention showed no clear difference in major bleeding events (timing not specified) (moderate certainty).
1 finding from 1 review
Intervention not reported
Minor bleeding events (timing not specified) · children with congenital heart disease undergoing CC
The intervention showed no clear difference in minor bleeding events (timing not specified) (moderate certainty).
1 finding from 1 review
Intervention not reported
Other thrombotic events: venous thrombosis (up to 48 hours after CC) · children with congenital heart disease undergoing CC
The intervention showed no clear difference in other thrombotic events: venous thrombosis (up to 48 hours after CC) (moderate certainty).
1 finding from 1 review
Incidence of recurrent VTE1 after initial treatment (up to 15 days) · patients with venous thromboembolism.
LMWH probably leads to lower incidence of recurrent VTE1 after initial treatment (up to 15 days) compared with UFH (moderate certainty).
1 finding from 1 review
Recurrent VTE · patients with venous thromboembolism.
LMWH probably leads to lower incidence of recurrent VTE1 (3 months compared with UFH (moderate certainty).
2 findings from 1 review
Reduction in thrombus size (pre‐ and post‐treatment venograms) · patients with venous thromboembolism.
LMWH may leads to lower reduction in thrombus size (pre‐ and post‐treatment venograms) compared with UFH (low certainty).
1 finding from 1 review
Major bleeding · patients with venous thromboembolism.
LMWH probably leads to lower incidence of major haemorrhagic episodes (during initial treatment ‐… compared with UFH (moderate certainty).
1 finding from 1 review
Overall mortality (end of · patients with venous thromboembolism.
LMWH showed no clear difference in overall mortality (end of compared with UFH (moderate certainty).
1 finding from 1 review
Recurrent VTE · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
LMWH showed no clear difference in incidence of recurrent VTE (treatment duration 3 months) compared with VKA (moderate certainty).
1 finding from 1 review
Major bleeding · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
LMWH may leads to lower incidence of major bleeding (treatment duration 3 months) compared with VKA (low certainty).
1 finding from 1 review
Mortality (treatment duration 3 months) · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
LMWH showed no clear difference in mortality (treatment duration 3 months) compared with VKA (moderate certainty).
1 finding from 1 review
Intervention not reported
HIT in people undergoing major surgical procedures · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days
The intervention may leads to lower HIT in people undergoing major surgical procedures (low certainty).
1 finding from 1 review
Intervention not reported
HIT complicated by venous thromboembolism · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days
The intervention may leads to lower HIT complicated by venous thromboembolism (low certainty).
1 finding from 1 review
Intervention not reported
Days of catheter patency · Children with central venous catheter
1 finding from 1 review
Intervention not reported
Catheter‐related thrombosis at any time during catheter stay · Children with central venous catheter
The intervention showed no clear difference in catheter‐related thrombosis at any time during catheter stay (moderate certainty).
1 finding from 1 review